Zydus, Torrent Pharma join hands to co-market Semaglutide injection

Under the terms of the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name Sembolic

Zydus Lifesciences and Torrent Pharmaceuticals have inked a licensing and supply agreement to co-market diabetes treatment medication Semaglutide Injection in the Indian market.

Under the terms of the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name Sembolic, leveraging its strong presence in chronic therapies and extensive field force across the country, the Gujarat-based drugmaker said in a statement.

As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus, it added.

Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable pen device.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. It is also indicated for chronic weight management in adults.